PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

Spravato, which is derived from ketamine, is not a new drug—it first ... Despite the approval, Johnson & Johnson’s stock (JNJ) dipped Wednesday after the company’s quarterly earnings release.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal ... Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019.